Articles
| Open Access |
DOI: OCT CHANGES IN MACULAR RETINAL THICKNESS DURING A-VEGF THERAPY
Normatova Nargiza Mirshovkatovna , Doctor Of Medical Sciences, Associate Professor, Center For The Development Of Professional Qualifications Of Medical Personnel, Uzbekistan Khamidullayev Firdavs Faridovich , Samarkand State Medical University, UzbekistanAbstract
Macular edema is the leading cause of vision loss in the increasingly frequent occurrence of diabetes mellitus, a true epidemic in developed countries. Diabetic macular edema is closely related to lifestyle, obesity, smoking or high blood pressure. Macular oedema is the leading cause of vision loss in people with diabetes in developed countries, and its prevalence is directly related to the duration of diabetes. Its incidence varies from publication to publication, ranging between 7.5% and 15.2%, and is more common in patients with type 2 diabetes receiving insulin.The significance of the incidence of diabetic macular oedema is directly related to the patient's metabolic control and the presence of risk factors, as we will see below.
Keywords
Macular edema, brolicizumab, retina.
References
SeddonJM, ChenCA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2014;44:17–39.
Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2014;291:1900–1901.
Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 2014;102:1640–1642.
Funk M, Karl D, Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2019;116:2393–2399.
Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2013;22:721–748
Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2016;141:456–462.
Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2015;46:726–733.
Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2017;67:1201–1206.
Full prescribing information. South San Francisco, CA: Genentech, Inc; Jun, 2010. Lucentis (ranibizumab injection)
Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.
Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology 93:1617-1620, 2016.
Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2017;85:425–430.
European Medicines Agency. Assessment report for Lucentis (ranibizumab) [Accessed May 17, 2022]. Procedure no: EMEA/H/C/000715/II/0020 .
Tolentino M. Systemic and ocular safety of intravitreal anti- VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2021;56(2):95–113.
Article Statistics
Copyright License
Copyright (c) 2023 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.